“Juniper Biologics is focused on therapy areas in which we can make the most difference – oncology, gene therapy and rare/orphan diseases,” a ...
https://www.google.com/url?rct=j&sa=t&url=https://www.bioworld.com/articles/518583-juniper-acquires-infigratinib-rights-from-helsinn-in-emerging-markets&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw2bV6_-A5kakQVIH1ekuf6M
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.